Vivos, Inc. is a radiation oncology medical device company. The company is headquartered in Richland, Washington. The company went IPO on 2001-08-08. The firm has developed an Yttrium-90-based injectable Precision Radionuclide Therapy medical device to treat tumors in animals (IsoPet) and humans (RadioGel). Using the Company’s proprietary hydrogel technology, PRnT uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows the safe delivery of higher doses needed for treating non-resectable and radiation-resistant cancers. University veterinary hospitals use the IsoPet Solutions division to demonstrate animal cancers’ safety and therapeutic effectiveness. RadioGel is a hydrogel liquid containing tiny yttrium-90 phosphate microparticles that may be administered directly into a tumor.
Follow-Up Questions
Who is the CEO of Vivos Inc?
Dr. Michael Korenko is the President of Vivos Inc, joining the firm since 2009.
What is the price performance of RDGL stock?
The current price of RDGL is $0.0933, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Vivos Inc?
Vivos Inc belongs to Health Care industry and the sector is Health Care
